前列腺癌筛查中省略系统穿刺活检的诊断影响
基于STHLM3-MRI试验中7609名50-74岁男性数据,评估省略系统穿刺对前列腺癌筛查诊断的影响。仅行靶向穿刺较联合穿刺降低ISUP GG≥2前列腺癌检出(RR 0.85),但ISUP GG 1检出降低幅度更小(RR 0.83),且增加根治性前列腺切除术后病理升级风险。
要点
- 省略系统穿刺降低ISUP GG≥2前列腺癌检出(RR 0.85,95%CI 0.81-0.90)。
- 每避免1例ISUP GG 1前列腺癌,伴随遗漏3.8例ISUP GG≥2和1.1例ISUP GG≥3前列腺癌。
- 根治性前列腺切除术后,仅靶向穿刺组病理升级率31.5% vs 联合穿刺组19.2%(p<0.05)。
核心结论
- 在前列腺癌筛查中完全省略系统穿刺与显著前列腺癌检出减少相关,同时仅较小程度减少无显著意义前列腺癌的过度检出,并增加组织病理学错误分类风险。
研究设计与样本
- 研究使用STHLM3-MRI试验数据,共7609名50-74岁男性随机接受磁共振成像(MRI)检查(前列腺特异性抗原[PSA]≥3 ng/ml或Stockholm3≥11%为高风险)。
- PI-RADS≥3的参与者接受靶向和系统穿刺,比较联合穿刺与仅靶向穿刺的癌症检出率(以风险比[RR]表示),并按年龄、PSA密度(PSAd)和PI-RADS进行亚组分析。
主要发现
- 参与者中位年龄66岁(四分位距61-71),中位PSA 3.8 ng/ml(2.9-5.8)。
- 395名接受联合穿刺的男性中,52名(13.2%)为ISUP GG 1,230名(58%)为ISUP GG≥2前列腺癌。
- 省略系统穿刺降低癌症检出率:ISUP GG 1的RR为0.83(95%CI 0.64-1.07),ISUP GG≥2的RR为0.85(95%CI 0.81-0.90),ISUP GG≥3的RR为0.86(95%CI 0.79-0.95)。
- 每避免1例ISUP GG 1癌症,伴随3.8例ISUP GG≥2和1.1例ISUP GG≥3癌症的遗漏。
- 在146名接受根治性前列腺切除术的男性中,仅靶向穿刺组46名(31.5%)发生病理升级,联合穿刺组28名(19.2%)发生病理升级(p<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The optimal biopsy strategy in prostate cancer screening is unknown. This study aims to assess the diagnostic effects of omitting systematic biopsies in a screening cohort. METHODS: We used data from the STHLM3-MRI trial. A total of 7609 men aged 50-74 yr were randomised to undergo magnetic resonance imaging (MRI) if having an elevated risk of prostate cancer (prostate-specific antigen [PSA] ≥3 ng/ml or Stockholm3 ≥11%). Participants with Prostate Imaging Reporting and Data System (PI-RADS) ≥3 underwent targeted and systematic biopsies. Cancer detection rates from combined and targeted-only biopsies were presented as a risk ratio (RR). Subgroup analyses were stratified by age, PSA density (PSAd), and PI-RADS. Differences in reclassification rates at radical prostatectomy were calculated. KEY FINDINGS AND LIMITATIONS: The median age of the participants was 66 yr (interquartile range: 61-71) and PSA 3.8 ng/ml (2.9-5.8). Out of 395 men undergoing combined biopsies, 52 (13.2%) had International Society of Urological Pathology (ISUP) grade group (GG) 1 and 230 (58%) had ISUP GG ≥2 prostate cancer. Omission of systematic biopsies reduced cancer detection rates (RR of ISUP GG 1: 0.83 [95% confidence interval 0.64-1.07]; ISUP GG ≥2: 0.85 [0.81-0.90]; and ISUP GG ≥3: 0.86 [0.79-0.95]). Each case of averted ISUP GG 1 cancer was associated with 3.8 cases of missed ISUP GG ≥2 and 1.1 case of ISUP GG ≥3 cancer. Detection of fewer ISUP GG ≥2 cases than the number of avoided ISUP 1 cancer cases was observed in all subgroups when systematic biopsies were omitted. Using PSAd ≥0.05 ng/ml2 as a cut-off for a biopsy resulted in the same numbers of ISUP GG 1 tumours saved, with higher detection rates of ISUP GG ≥2 tumours. In 146 men undergoing radical prostatectomy, 46 (31.5%) versus 28 (19.2%) were upgraded following targeted biopsies versus a combined biopsy strategy (p < 0.05). CONCLUSIONS AND CLINICAL IMPLICATIONS: Complete omission of systematic biopsies in prostate cancer screening is associated with decreased detection of significant cancer, while reducing overdetection of insignificant cancer to a smaller extent. This strategy also increased the risk of histopathological misclassification. PATIENT SUMMARY: In a prostate cancer screening setting, we examined the diagnostic effects of systematic biopsies in addition to targeted biopsies in men with suspicious magnetic resonance imaging lesions. We found that exclusion of systematic biopsies led to reduced detection of clinically significant prostate cancer. Our findings emphasise the importance of incorporating systematic biopsies alongside targeted biopsies for improved diagnostic outcomes.
引用
- Chandra Engel J, Eklund M, Jäderling F, et al. Diagnostic Effects of Omitting Systematic Biopsies in Prostate Cancer Screening. Eur Urol Oncol. 2024. PMID: 39443223. doi:10.1016/j.euo.2024.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。